Lineage Cell Therapeutics (LCTX) Current Deferred Revenue (2010 - 2026)

Lineage Cell Therapeutics' Current Deferred Revenue history runs 17 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 75.24% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 75.24% decrease from a year earlier, with the FY2025 full-year figure at $3.3 million, down 54.89% from the prior year.
• Current Deferred Revenue slipped to $1.7 million in Q1 2026 per LCTX's latest filing, from $3.3 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $45.6 million in Q1 2022 and bottomed at $1.7 million in Q1 2026.
• The 5-year median for Current Deferred Revenue is $9.4 million (2022), against an average of $12.2 million.
• Across the five-year window, Current Deferred Revenue surged 45048.51% in 2022 and plunged 75.88% in 2023, its largest moves.
• Year by year, Current Deferred Revenue stood at $9.4 million in 2022, then climbed by 14.72% to $10.8 million in 2023, then plunged by 31.64% to $7.4 million in 2024, then plunged by 54.89% to $3.3 million in 2025, then sank by 48.51% to $1.7 million in 2026.
• Per Business Quant, the three latest LCTX Current Deferred Revenue figures stand at $1.7 million (Q1 2026), $3.3 million (Q4 2025), and $3.8 million (Q3 2025).